Amirchaghmaghi 2016.

Methods	Study design: RCT Conducted in Iran Number of centres: 1 Recruitment period: October 2012 to June 2013 Funding source: supported by Vice Chancellory of Mashhadd University of Medical Sciences
Participants	Inclusion criteria: people with clinical signs of erosive‐atrophic OLP which was confirmed by clinical and histopathological examination Exclusion criteria: pregnancy; breastfeeding; current use of anticoagulants or antiplatelet agents; current orthodontic treatment; history of gastric ulcers, duodenal ulcers, gallstones, hepatic diseases, any existing malignancy or viral infection in mouth; receiving any topical treatment for OLP in the past 2 weeks or any systemic treatment for OLP in the past 4 weeks; use of azathioprine, ciclosporin or receiving PUVA, UVA or UVB in the last month; history of allergy to corticosteroids or curcumin Group A: randomised 12; analysed 12 Group B: randomised 8; analysed 8
Interventions	Group A: 1 dexamethasone mouthwash 0.5 mg 3 times daily + 1 nystatin (100,000 units) suspension 3 times daily + 4 curcumin tablets (500 mg) twice daily for 4 weeks Group B: 1 dexamethasone mouthwash 0.5 mg 3 times daily + 1 nystatin (100,000 units) suspension 3 times daily + 4 placebo tablets twice daily for 4 weeks
Outcomes	Pain (VAS), clinical score (Thongprasom), complete resolution, adverse effects Measured at baseline, 14 days and 28 days
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Randomization was performed using a computer‐generated random number table."
Allocation concealment (selection bias)	Low risk	Quote: "Randomization was performed using a computer‐generated random number table. Study medication tablets with 95% curcominoids (Samilabs Limited, Bangalore, India) and identical placebo tablets (containing lactose) were prepackaged by a university pharmacist in identical containers. During treatment, both of the practitioners and the patients were unaware of medications they were using."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "During treatment, both of [sic] the practitioners and the patients were unaware of medications they were using."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "During treatment, both of [sic] the practitioners and the patients were unaware of medications they were using."
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: no missing data. All randomised participants included in the result analysis.
Selective reporting (reporting bias)	Low risk	Planned outcomes reported.
Other bias	Low risk	No other sources of bias identified.